Low Incidence of Diabetic Ketoacidosis With Canagliflozin
Canagliflozin-treated patients with type 2 diabetes have low incidence of serious adverse DKA events
FDA Approves Balloon Device to Treat Obesity
Inflated in stomach, it may create sense of fullness
Outcomes Equal for Continuous, Intermittent β-Lactams in Sepsis
No differences in ICU-free days, 90-day survival, organ failure-free days, bacteremia duration
Similar Adverse Effects Seen for St. John’s Wort, Fluoxetine
Majority reported concern females, 26 to 50 years of age
Routine Dyspnea Severity Assessment Could Aid Care
Regular appraisal in cardiopulmonary disease patients would aid hospitalists' decision making
2015 MOC Program Expected to Cost $5.7 Billion Over 10 Years
Time costs account for 90 percent of maintenance of certification costs, estimated at $5.1 billion
Early Invasive Strategy No Benefit 10 Years After NSTE-ACS
No improved outcomes versus selective invasive strategy in non-ST segment acute coronary syndrome
2008 Initiative Had Minimal Impact on Pressure Ulcer Charges
Hospital-Acquired Conditions Initiative cut payment in 0.003 percent of discharges
Higher Health Costs for Diabetes Mainly Meds, Inpatient Care
Individuals with diabetes had more than double the unadjusted mean direct expenditures over 10 years
Not All Placebos Are Equal in Knee Osteoarthritis
Differential placebo effects can alter estimates of the relative efficacies of active treatments
